This supports the use of PD-L2 expression analyses, beyond PD-L1 expression analyses, to predict responsiveness to immunotherapy with PD-1/PD-L1 axis blockade in NSCLC. The gene discussed is PDCD1LG2; the disease is non-small cell lung carcinoma.